The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prognostic and predictive blood-based biomarkers (BMs) in patients (pts) with advanced epithelial ovarian cancer (EOC) treated with carboplatin–paclitaxel (CP) ± bevacizumab (BEV): Results from GOG-0218.
 
Angeles Alvarez Secord
Honoraria - AstraZeneca; Genentech/Roche; Janssen
Consulting or Advisory Role - AstraZeneca; Genentech/Roche; Janssen
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Endocyte (Inst); Exelixis (Inst); Genentech (Inst); Incyte (Inst); Morphotek (Inst); Prima BioMed (Inst); Tesaro (Inst)
 
David Tritchler
No Relationships to Disclose
 
Yingmiao Liu
No Relationships to Disclose
 
Mark D. Starr
Patents, Royalties, Other Intellectual Property - Duke Cancer Institute (Inst)
 
John C. Brady
No Relationships to Disclose
 
Heather A. Lankes
No Relationships to Disclose
 
Herbert Hurwitz
Honoraria - Genentech/Roche; Lilly/ImClone
Consulting or Advisory Role - Acceleron Pharma; Bristol-Myers Squibb; Genentech/Roche; GlaxoSmithKline; Incyte; Lilly; Novartis; OncoMed; TRACON Pharma
Research Funding - Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Macrogenics (Inst); NCI (Inst); Novartis (Inst); Regeneron (Inst); TRACON Pharma (Inst)
 
Robert S. Mannel
No Relationships to Disclose
 
Krishnansu Sujata Tewari
Consulting or Advisory Role - Roche/Genentech
Speakers' Bureau - AstraZeneca; Merck; Roche/Genentech
Travel, Accommodations, Expenses - Roche/Genentech
 
David M. O'Malley
Consulting or Advisory Role - Eisai; Janssen Oncology
Research Funding - Ajinomoto (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Clovis Oncology (Inst); EMD Serono (Inst); Ergomed (Inst); Genentech/Roche (Inst); Immunogen (Inst); Janssen Research & Development (Inst); Regeneron (Inst); VentiRx (Inst)
 
Heidi J. Gray
No Relationships to Disclose
 
Jamie Nadine Bakkum-Gamez
No Relationships to Disclose
 
Keiichi Fujiwara
Honoraria - Chugai Pharma; Eisai; Kyowa Hakko Kirin; Nippon Kayaku; Taiho Pharmaceutical; Yakult Honsha; Zeria Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; MSD; Pfizer
Research Funding - Chugai Pharma (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Johnson & Johnson (Inst); Kaken Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst)
Travel, Accommodations, Expenses - Pfizer
 
Matthew Boente
No Relationships to Disclose
 
Wei Deng
No Relationships to Disclose
 
Robert Allen Burger
Consulting or Advisory Role - Boehringer Ingelheim; Genentech/Roche; Janssen Research & Development; Nucana; Oxigene
 
Michael J. Birrer
Consulting or Advisory Role - AstraZeneca; Roche/Genentech
 
Andrew B. Nixon
Consulting or Advisory Role - Cerulean Pharma; Novartis; Pfizer
Research Funding - Amgen; Incyte; Novartis; TRACON Pharma
Patents, Royalties, Other Intellectual Property - Patent pending (Inst); Patent Pending (Inst)